Dosing and uses of Maginex, Maginex DS (magnesium aspartate)
Adult dosage forms and strengths
tablet, enteric-coated
- 61mg elemental Mg (615mg salt form)
granules for oral solution
- 122mg elemental Mg/packet (1230mg salt form)
Magnesium Supplementation
19-30 years
- Elemental magnesium
- Males: 400mg/day
- Females: 310mg/day
- Pregnant females: 350mg/day
- Lactation: 310mg/day
>30 years
- Elemental magnesium
- Males: 420mg/day
- Females: 320mg/day
- Pregnant females: 360mg/day
- Lactation: 320mg/day
OTC Supplement
- Salt form
- 1 packet (dissolved in water or juice) or 2 tablets (1230 mg) up to 3 times daily
Pediatric dosage forms and strengths
(tablet, enteric-coated)
- 61mg elemental Mg (615mg salt form)
(powder for oral solution)
- 122mg elemental Mg/packet (1230mg salt form)
Magnesium Supplementation
Dietary reference intake for elemental magnesium varies in children according to age
<6 months: 30 mg/day
6-12 months: 75 mg/day
1-3 years: 80 mg/day
3-8 years: 130 mg/day
8-13 years: 240 mg/day
Adolescent boys 13-18 years: 410 mg/day
Adolescent girls
- 13-18 years: 360 mg/day
- Pregnant: 400 mg/day
- Lactating: 360 mg/day
Maginex, Maginex DS (magnesium aspartate) adverse (side) effects
Frequency not defined
Diarrhea
Cramps
Gas formation
Warnings
Contraindications
Hypersensitivity
Cautions
Hypermagnesemia may result with renal impairment
May aggravate existing heart disease
Caution in patients with myasthenia gravis or other neuromuscular disease
Accumulation of magnesium in renal impairment may lead to magnesium intoxication
Magnesium toxicity characterized by flushing, diaphoresis, hypotension, depressed deep tendon reflexes, muscle paralysis, weakness, hypothermia, circulatory collapse, and cardiac, CNS, or respiratory depression
Pregnancy and lactation
Pregnancy category: A; elemental magnesium dietary reference intake during pregnancy is 350-400 mg/day for adult women
Lactation: Distributed in breast milk, elemental magnesium dietary reference intake for breast feeding women is 310-360 mg/day for adult women
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Maginex, Maginex DS (magnesium aspartate)
Mechanism of action
Cofactor for many enzymatic pathways involved in phosphate transfer reactions that use ATP and other nucleotides as substrates (eg, oxidative phosphorylation, oxygen radical reduction); involved in enzymatic reactions responsible for carbohydrate metabolism and protein synthesis
May play a role in reducing serum cholesterol and sodium/potassium ATPase responsible for neuromuscular functioning
Pharmacokinetics
Excretion: Urine
